Calidi Biotherapeutics completed its merger with First Light Acquisition Group on May 12, taking the San Diego-based cell therapy developer public through a SPAC transaction that values the combined entity at approximately $200 million pre-money. The deal includes a $90 million PIPE commitment from institutional healthcare investors and anchored by accounts that previously backed Sorrento Therapeutics and ImmunityBio. Calidi's lead program, NeuroNova, uses genetically modified neural stem cells loaded with oncolytic viruses to target recurrent glioblastoma, a brain cancer with median survival under fifteen months post-diagnosis.

First Light raised $115 million in its January 2021 IPO but traded below $10.00 net asset value for seventeen consecutive months before announcing the Calidi combination in November 2024. The trust redemption rate hit 87%, leaving roughly $15 million in the balance sheet before the PIPE closed. Calidi's founder, Dr. Santosh Kesari, previously led neuro-oncology at UC San Diego and co-authored forty-three peer-reviewed papers on stem cell therapeutics between 2008 and 2023. The company holds exclusive licenses to neural stem cell manufacturing protocols developed at City of Hope and Harvard's Brigham and Women's Hospital.

The NeuroNova platform matters because it sidesteps blood-brain barrier challenges that limit systemic chemotherapy efficacy in glioblastoma patients. Neural stem cells migrate toward tumor sites and deliver payloads—currently oncolytic adenoviruses engineered to replicate selectively in cancer cells—directly into the tumor microenvironment. Calidi initiated a Phase I/II trial in recurrent glioblastoma in Q4 2023, dosing twelve patients at escalating cell concentrations. Early pharmacodynamic data showed measurable viral replication in resected tumor samples at day fourteen post-infusion, and two patients remained progression-free beyond nine months. The trial targets forty patients by Q1 2026 with interim data expected in Q3 2025.

The SPAC structure brought Calidi public eighteen months faster than a traditional IPO would have allowed, preserving cash that otherwise funds roadshow and underwriting fees. The $90 million PIPE backstop came from accounts including Opaleye Management, Tang Capital Partners, and Sio Capital, three firms that concentrate in Phase II oncology assets with binary catalyst timelines. Post-merger, Calidi holds roughly $102 million in pro forma cash, enough to fund operations through mid-2026 without additional dilution, assuming the NeuroNova trial remains on schedule and burn stays below $3.5 million monthly.

Operators should track three items. First, the interim data readout in Q3 2025 will include progression-free survival curves and response rate by cohort, the first real test of whether the viral payload drives measurable tumor reduction. Second, Calidi's manufacturing agreement with City of Hope expires in December 2025, and any renegotiation or shift to contract manufacturing could compress margins or delay production scale-up. Third, the lock-up on founder and PIPE shares lifts in November 2025, introducing 42 million shares to the float and potential downward pressure if insiders derisk before pivotal data.

The capital structure now supports a binary bet: if NeuroNova shows durable response rates above 20% in recurrent glioblastoma, Calidi trades toward oncology comps in the $600 million to $800 million range; if pharmacodynamics fail to translate into survival benefit, the equity reprices below net cash within two quarters.